Last reviewed · How we verify
fingolimob (FTY)
Fingolimob is a sphingosine-1-phosphate (S1P) receptor modulator that sequesters lymphocytes in lymphoid tissues, reducing their migration to inflamed sites.
Fingolimob is a sphingosine-1-phosphate (S1P) receptor modulator that sequesters lymphocytes in lymphoid tissues, reducing their migration to inflamed sites. Used for Relapsing-remitting multiple sclerosis.
At a glance
| Generic name | fingolimob (FTY) |
|---|---|
| Sponsor | University Hospital, Clermont-Ferrand |
| Drug class | Sphingosine-1-phosphate receptor modulator |
| Target | S1P1 receptor (sphingosine-1-phosphate receptor 1) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Fingolimob binds to sphingosine-1-phosphate receptors on lymphocytes, particularly S1P1, causing internalization and degradation of the receptor. This prevents lymphocyte egress from secondary lymphoid organs into the peripheral circulation, thereby reducing infiltration of autoreactive immune cells into target tissues. This mechanism is particularly effective in multiple sclerosis where it reduces relapse rates and disability progression.
Approved indications
- Relapsing-remitting multiple sclerosis
Common side effects
- Headache
- Liver enzyme elevation
- Bradycardia
- Macular edema
- Infection
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |